News | June 21, 2026
LabGenius and LG Chem strike AI-powered deal to develop next-gen tumour-targeting antibody therapy
The collaboration is focused on overcoming a major limitation in existing cancer drugs
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Healthcare speed-scaling platform offers clinical validation, regulatory support, mentorship, and investor access to startups working across preventive health, oncology, genomics, diagnostics, and digital health
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The new institute will strengthen oncology infrastructure in central India with advanced radiation therapy, multidisciplinary expertise, and comprehensive cancer care services
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Subscribe To Our Newsletter & Stay Updated
